| For: |
Sugimoto M, Furuta T. Efficacy of tailored |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i21/6400.htm |
| Number | Citing Articles |
| 1 |
Kee Don Choi. Current Trends ofHelicobacter pyloriEradication in Korea. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2015; 15(3) doi: 10.7704/kjhugr.2015.15.3.147
|
| 2 |
Lili Yang, Ao Zou, Huihua Wu, Hai Guo, Fangting Zhang, Bing Zou, Junping Wang, Emily Chia-Yu Su. Application of Visual Gene Clip‐Based Tailored Therapy for the Eradication of Helicobacter pylori. BioMed Research International 2021; 2021(1) doi: 10.1155/2021/6150628
|
| 3 |
P Malfertheiner, F Megraud, C A O'Morain, J P Gisbert, E J Kuipers, A T Axon, F Bazzoli, A Gasbarrini, J Atherton, D Y Graham, R Hunt, P Moayyedi, T Rokkas, M Rugge, M Selgrad, S Suerbaum, K Sugano, E M El-Omar. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut 2017; 66(1) doi: 10.1136/gutjnl-2016-312288
|
| 4 |
Han Chen, Yini Dang, Xiaoying Zhou, Bingtuan Liu, Shiyu Liu, Guoxin Zhang. Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication. Medicine 2016; 95(7) doi: 10.1097/MD.0000000000002750
|
| 5 |
Muhammad Miftahussurur, Yoshio Yamaoka. Appropriate First-Line Regimens to Combat Helicobacter pylori Antibiotic Resistance: An Asian Perspective. Molecules 2015; 20(4) doi: 10.3390/molecules20046068
|
| 6 |
Adel Elrakeeb, Sawsan H. Eltayyeb, Amr Elgazzar, Abdelaleem A. Elgendy, Mohamed Alboraie. Tailored Helicobacter pylori therapy is more effective than conventional therapy. Al-Azhar Assiut Medical Journal 2021; 19(3) doi: 10.4103/azmj.azmj_51_21
|
| 7 |
Ayman Elbehiry, Eman Marzouk. Helicobacter pylori Eradication in the Era of Antibiotic Resistance: From Universal Regimens to Precision-Guided Management. Antibiotics 2026; 15(7) doi: 10.3390/antibiotics15070673
|
| 8 |
Muhammad Miftahussurur, Yoshio Yamaoka. Diagnostic Methods ofHelicobacter pyloriInfection for Epidemiological Studies: Critical Importance of Indirect Test Validation. BioMed Research International 2016; 2016 doi: 10.1155/2016/4819423
|
| 9 |
Varocha Mahachai, Ratha‐korn Vilaichone, Rapat Pittayanon, Jarin Rojborwonwitaya, Somchai Leelakusolvong, Monthira Maneerattanaporn, Peranart Chotivitayatarakorn, Sombat Treeprasertsuk, Chomsri Kositchaiwat, Pises Pisespongsa, Pisaln Mairiang, Aziz Rani, Alex Leow, Swe Mon Mya, Yi‐Chia Lee, Sengdao Vannarath, Bouachanh Rasachak, Oung Chakravuth, Moe Myint Aung, Tiing‐Leong Ang, Jose D Sollano, Duc Trong Quach, Inchaya Sansak, Olarn Wiwattanachang, Piyathida Harnsomburana, Ari Fahrial Syam, Yoshio Yamaoka, Kwong‐Ming Fock, Khean‐Lee Goh, Kentaro Sugano, David Graham. Helicobacter pylori management in ASEAN: The Bangkok consensus report. Journal of Gastroenterology and Hepatology 2018; 33(1) doi: 10.1111/jgh.13911
|
| 10 |
Chonticha Auesomwang, Monthira Maneerattanaporn, William D Chey, Pattarachai Kiratisin, Somchai Leelakusolwong, Tawesak Tanwandee. Ten‐day high‐dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology 2018; 33(11) doi: 10.1111/jgh.14292
|
| 11 |
Anne Donnars, Julie Cremniter, Chloé Plouzeau, Anthony Michaud, Lauranne Broutin, Christophe Burucoa, Maxime Pichon. Comparison of three different molecular biology assays (AllPlexTM H. pylori & ClariR assay, Amplidiag® H. pylori + ClariR and RIDA®GENE Helicobacter pylori) to detect Helicobacter pylori and clarithromycin resistance in stool samples. Diagnostic Microbiology and Infectious Disease 2025; 112(2) doi: 10.1016/j.diagmicrobio.2025.116771
|
| 12 |
Kyoung Hwa Lee, Soon Young Park, Su Jin Jeong, Da Hyun Jung, Jie-Hyun Kim, Seok Hoon Jeong, Il-Mo Kang, Young Goo Song. Can Aminoglycosides Be Used as a New Treatment forHelicobacter pylori?In vitroActivity of Recently IsolatedHelicobacter pylori. Infection & Chemotherapy 2019; 51(1) doi: 10.3947/ic.2019.51.1.10
|
| 13 |
Larisa H Cavallari, Kristin W Weitzel, Amanda R Elsey, Xinyue Liu, Scott A Mosley, Donald M Smith, Benjamin J Staley, Almut G Winterstein, Carol A Mathews, Francesco Franchi, Fabiana Rollini, Dominick J Angiolillo, Petr Starostik, Michael J Clare-Salzler, David R Nelson, Julie A Johnson. Institutional Profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics 2017; 18(5) doi: 10.2217/pgs-2017-0028
|
| 14 |
Chan-Juan Fan. Efficacy assessment of diverse antibiotic combinations in bismuth quadruple regimens and risk factors for Helicobacter pylori eradication: a retrospective single-center study in China. International Journal of Clinical and Experimental Medicine 2024; 17(5) doi: 10.62347/SMLE6245
|
| 15 |
Liem T. Nguyen, Vuong B. Nguyen, Tu V. Tran, Loan T. T. Le, Mai H. T. Phuong, Thang Nguyen. Effects of the EM CYP2C19 type and MDR1 3435CC gene on Helicobacter pylori eradication rate in patients with duodenal ulcer by the four-drug regimen of rabeprazole, bismuth, tetracycline, and tinidazole. Pharmacia 2024; 71 doi: 10.3897/pharmacia.71.e108090
|
| 16 |
Michael Dore, Blake Cirks, Todd Gleeson. Eradicating Multi-Drug-Resistant Helicobacter pylori with Four Times Daily Lansoprazole. The American Journal of Medicine 2016; 129(4) doi: 10.1016/j.amjmed.2015.11.025
|
| 17 |
Youn I Choi, Jun-Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung Ho Kim, Ja Young Seo, Dong Kyun Park. Tailored eradication strategy <i>vs</i> concomitant therapy for <i>Helicobacter pylori</i> eradication treatment in Korean patients. World Journal of Gastroenterology 2021; 27(31): 5247-5258 doi: 10.3748/wjg.v27.i31.5247
|
| 18 |
Han Minh Thuy, Mitsushige Sugimoto, Pham Minh Ngoc Quang, Yoshio Yamaoka. CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use. Expert Review of Clinical Pharmacology 2026; 19(2) doi: 10.1080/17512433.2026.2626454
|
| 19 |
Peter Malfertheiner, M. Constanza Camargo, Emad El-Omar, Jyh-Ming Liou, Richard Peek, Christian Schulz, Stella I. Smith, Sebastian Suerbaum. Helicobacter pylori infection. Nature Reviews Disease Primers 2023; 9(1) doi: 10.1038/s41572-023-00431-8
|
| 20 |
Nataliya Pidkovka, Olena Rachkevych, Abbes Belkhiri. Extrahepatic cytochrome P450 epoxygenases: pathophysiology and clinical significance in human gastrointestinal cancers. Oncotarget 2021; 12(4) doi: 10.18632/oncotarget.27893
|
| 21 |
Ali F. Altebainawi, Lulwa A. Alfaraj, Amjad A. Alharbi, Fadwa F. Alkhuraisi, Thamir M. Alshammari. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. Therapeutic Advances in Drug Safety 2023; 14 doi: 10.1177/20420986231154075
|
| 22 |
Colin W. Howden, Kely L. Sheldon, June S. Almenoff, William D. Chey. Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data. Digestive Diseases and Sciences 2022; 67(9) doi: 10.1007/s10620-021-07323-5
|
| 23 |
Nihal El Rouby, John J. Lima, Julie A. Johnson. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism & Toxicology 2018; 14(4) doi: 10.1080/17425255.2018.1461835
|
| 24 |
Michiel C. Mommersteeg, Stella A. V. Nieuwenburg, Leonieke M. M. Wolters, Buddy H. C. M. Roovers, Hanneke A. J. van Vuuren, Auke P. Verhaar, Marco J. Bruno, Ernst J. Kuipers, Maikel P. Peppelenbosch, Manon C. W. Spaander, Gwenny M. Fuhler. The use of non‐invasive stool tests for verification of Helicobacter pylori eradication and clarithromycin resistance. United European Gastroenterology Journal 2023; 11(9) doi: 10.1002/ueg2.12473
|
| 25 |
Haoran Ke, Jing Li, Bingyun Lu, Chenghai Yang, Jiamin Wang, Zhiqing Wang, Le Liu, Ye Chen. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth‐based quadruple therapy. Helicobacter 2021; 26(1) doi: 10.1111/hel.12768
|
| 26 |
Azucena Arévalo Galvis, Alba Alicia Trespalacios Rangel, William Otero Regino. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first‐line triple therapy. Helicobacter 2019; 24(3) doi: 10.1111/hel.12574
|
| 27 |
Todor Asenov Angelov, Mila Dimitrova Kovacheva-Slavova, Hristo Ilianov Iliev, Hristo Yankov Valkov, Borislav Georgiev Vladimirov. Gastritis - New Approaches and Treatments. 2019; doi: 10.5772/intechopen.86963
|
| 28 |
Hyungchul Park, Jeong Hoon Lee. Recent Trends in Tailored Treatments for Helicobacter pylori Infection. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021; 21(2) doi: 10.7704/kjhugr.2021.0005
|
| 29 |
Baojun Suo, Xinlu Ren, Cailing Li, Yanyan Shi, Xueli Tian, Kai Zhou, Liya Zhou, Zhiqiang Song. Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Helicobacter 2025; 30(5) doi: 10.1111/hel.70082
|
| 30 |
Vladimir I. Simanenkov, Sergei A. Alekseenko. Prospects for personalized Helicobacter pylori eradication therapy. Pro et contra. Terapevticheskii arkhiv 2022; 94(8) doi: 10.26442/00403660.2022.08.201787
|
| 31 |
Xiao-Min Liao, Gao-Hui Nong, Mei-Zu Chen, Xue-Ping Huang, Yun-Yan Cong, Yi-Ying Huang, Bai-He Wu, Jin-Qi Wei. Modified sequential therapy <italic>vs</italic> quadruple therapy as initial therapy in patients with <italic>Helicobacter</italic> infection. World Journal of Gastroenterology 2015; 21(20): 6310-6316 doi: 10.3748/wjg.v21.i20.6310
|
| 32 |
Hitomi Ichikawa, Mitsushige Sugimoto, Ken Sugimoto, Akira Andoh, Takahisa Furuta. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. Journal of Gastroenterology and Hepatology 2016; 31(4) doi: 10.1111/jgh.13233
|
| 33 |
Nazlı Arslan, Özlem Yılmaz, Ebru Demiray-Gürbüz. Importance of antimicrobial susceptibility testing for the management of eradication in <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology 2017; 23(16): 2854-2869 doi: 10.3748/wjg.v23.i16.2854
|
| 34 |
Ravishankar Ram M., Xinsheng Teh, Tamayanthi Rajakumar, Khean Lee Goh, Alex Hwong Ruey Leow, Bee Hoon Poh, Vanitha Mariappan, Esaki M Shankar, Mun Fai Loke, Jamuna Vadivelu. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapy. Journal of Antimicrobial Chemotherapy 2019; 74(1) doi: 10.1093/jac/dky401
|
| 35 |
S. Yu. Serebrova, E. N. Kareva, D. O. Kurguzova, E. Yu. Demchenkova, N. N. Eremenko, I. A. Mazerkina, L. M. Krasnуkh, G. F. Vasilenko, A. B. Prokofiev. The role of clarithromycin in modern <i>Helicobacter pylori</i> eradication therapy regimens. Meditsinskiy sovet = Medical Council 2023; (8) doi: 10.21518/ms2023-128
|
| 36 |
Tsung‐Jung Lin, Hsi‐Chang Lee, Chih‐Lin Lin, Chung‐Kwe Wang, Kuan‐Yang Chen, Deng‐Chyang Wu. CYP2C19 polymorphism has no influence on rabeprazole‐based sequential therapy. Advances in Digestive Medicine 2017; 4(4) doi: 10.1002/aid2.12134
|
| 37 |
E. V. Luzina, A. A. Dutova, L. B. Lazebnik, N. V. Lareva. Treatment of <i>Helicobacter pylori</i> infection for medical professionals. Experimental and Clinical Gastroenterology 2023; (3) doi: 10.31146/1682-8658-ecg-211-3-28-40
|
| 38 |
M. Teng, A. L. Khoo, Y. J. Zhao, L. Lin, B. P. Lim, T. S. Wu, Y. Y. Dan. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori
infection. Journal of Clinical Pharmacy and Therapeutics 2015; 40(4) doi: 10.1111/jcpt.12277
|
| 39 |
Masaki Murata, Shin'ichi Miyamoto, Noriko Hayashi, Misae Ogaya, Koki Kurouchi, Yoichi Asano, Yuki Yamazaki, Sumire Mori, Hiroaki Yaku, Hirokazu Okada, Yoshiko Nakano, Yoshiyuki Ota, Yuichi Yamaga, Satoru Iwamoto, Taro Ueo. Vonoprazan‐Containing Triple Therapy Based on Clarithromycin Susceptibility May Be Definitive Treatment Strategy for Eradication of Helicobacter pylori. JGH Open 2026; 10(2) doi: 10.1002/jgh3.70357
|
| 40 |
. 2022; doi: 10.70675/3e69bd2az2801z4824zb869z1eb0f11f27ff
|
| 41 |
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Melissa Cortez Braga Maia, Guilherme Grossi Lopes Cançado. Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis. Journal of Gastroenterology and Hepatology 2026; 41(9) doi: 10.1111/jgh.70565
|
| 42 |
Luiz Gonzaga Vaz COELHO, James Ramalho MARINHO, Robert GENTA, Laercio Tenório RIBEIRO, Maria do Carmo Friche PASSOS, Schlioma ZATERKA, Paulo Pimentel ASSUMPÇÃO, Alfredo José A BARBOSA, Ricardo BARBUTI, Lucia Libanês BRAGA, Helenice BREYER, Aloisio CARVALHAES, Décio CHINZON, Marcelo CURY, Gerson DOMINGUES, Jorge Luiz JORGE, Ismael MAGUILNIK, Frederico Passos MARINHO, Joaquim Prado de MORAES-FILHO, José Miguel Luz PARENTE, Celso Mirra de PAULA-E-SILVA, José PEDRAZZOLI-JÚNIOR, Ana Flávia Passos RAMOS, Heinrich SEIDLER, José Nonato SPINELLI, José Vitor ZIR. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arquivos de Gastroenterologia 2018; 55(2) doi: 10.1590/s0004-2803.201800000-20
|
| 43 |
Tsung-Jung Lin, Hsi-Chang Lee, Chih-Lin Lin, Chung-Kwe Wang, Kuan-Yang Chen, Deng-Chyang Wu. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for <i>Helicobacter pylori</i> eradication. World Journal of Clinical Cases 2018; 6(12): 514-520 doi: 10.12998/wjcc.v6.i12.514
|
| 44 |
S. Yu. Serebrova, D. O. Kurguzova, L. M. Krasnykh, G. F. Vasilenko, E. Yu. Demchenkova, N. N. Eremenko, E. N. Kareva, A. B. Prokofiev. Kinetics of Omeprazole Release from Enteric Dosage Forms of Different Manufacturers. Pharmaceutical Chemistry Journal 2024; 57(10) doi: 10.1007/s11094-024-03060-x
|
| 45 |
Svetlana Serebrova, Daria Kurguzova, Lyudmila Krasnykh, Galina Vasilenko, Vladimir Drozdov, Natalia Lazareva, Eugenia Shikh, Marina Zhuravleva, Svetlana Rykova, Natalia Eremenko, Elena Kareva, Karin Mirzaev, Dmitriy Sychev, Alexey Prokofiev. Potential factors of Helicobacter pylori resistance to clarithromycin. Drug Metabolism and Personalized Therapy 2022; 37(4) doi: 10.1515/dmpt-2021-0193
|
| 46 |
Kiarash Ghazvini, Hossein Kamali, Seyed-Abolfazl Hosseininasab-nodoushan, Masoud Keikha. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis. Gene Reports 2021; 25 doi: 10.1016/j.genrep.2021.101340
|
| 47 |
Eunsun Lim, Ik Hyun Jo, Yeon-Ji Kim, Woo Chul Chung. In situ Diagnosis of Helicobacter pylori Infection Using the Endoscopic Kyoto Scoring System. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021; 21(4) doi: 10.7704/kjhugr.2021.0046
|
| 48 |
Liya Zhou, Jianzhong Zhang, Zhiqiang Song, Lihua He, Yanqing Li, Jiaming Qian, Peng Bai, Yan Xue, Ye Wang, Sanren Lin. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Helicobacter 2016; 21(2) doi: 10.1111/hel.12242
|
| 49 |
I. G. Paliy, S. V. Zaika, N. Kondratyuk, K. V. Ksenchyna. Basal gastric secretion as a prognostic criterion of proton pump inhibitors effectiveness. Reports of Vinnytsia National Medical University 2024; 28(2) doi: 10.31393/reports-vnmedical-2024-28(2)-16
|